[go: up one dir, main page]

PA8713501A1 - INHIBIDORES DE 11-BETA HIDROXIESTEROIDE DEHIDROGENASA - 11ßHSD1 - Google Patents

INHIBIDORES DE 11-BETA HIDROXIESTEROIDE DEHIDROGENASA - 11ßHSD1

Info

Publication number
PA8713501A1
PA8713501A1 PA20078713501A PA8713501A PA8713501A1 PA 8713501 A1 PA8713501 A1 PA 8713501A1 PA 20078713501 A PA20078713501 A PA 20078713501A PA 8713501 A PA8713501 A PA 8713501A PA 8713501 A1 PA8713501 A1 PA 8713501A1
Authority
PA
Panama
Prior art keywords
beta
hydroxiesteroid
11ßhsd1
dehydrogenasa
inhibitors
Prior art date
Application number
PA20078713501A
Other languages
English (en)
Inventor
Li Jianchang
Li Wei
Shaoyun Xiang Jason
Lee Jinbo
Wan Zhao-Kui
S Mansour Tarek
C Mckew John
L Lee Katherine
Saiah Eddine
Y Tam Steve
Chen Lihren
Ipek Manus
Li Huan-Qui
Suri Vipin
Vargas Richard
Wu Yuchuan
Binnun Eva
P Wilson Douglas
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of PA8713501A1 publication Critical patent/PA8713501A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
    • C07D211/96—Sulfur atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/22—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/22—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
    • C07D295/26—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyridine Compounds (AREA)
  • Steroid Compounds (AREA)

Abstract

LA PRESENTA INVENCIÓN SE RELACIONA CON COMPUESTOS INHIBIDORES DE 11-BETA HSD1, COMPOSICIONES FARMACÉUTICAS Y MÉTODOS PERTINENTES.
PA20078713501A 2006-02-07 2007-02-07 INHIBIDORES DE 11-BETA HIDROXIESTEROIDE DEHIDROGENASA - 11ßHSD1 PA8713501A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US77126206P 2006-02-07 2006-02-07

Publications (1)

Publication Number Publication Date
PA8713501A1 true PA8713501A1 (es) 2009-09-17

Family

ID=38236242

Family Applications (1)

Application Number Title Priority Date Filing Date
PA20078713501A PA8713501A1 (es) 2006-02-07 2007-02-07 INHIBIDORES DE 11-BETA HIDROXIESTEROIDE DEHIDROGENASA - 11ßHSD1

Country Status (18)

Country Link
US (2) US7632838B2 (es)
EP (1) EP1981848A2 (es)
JP (1) JP2009526059A (es)
KR (1) KR20080093072A (es)
CN (1) CN101400653A (es)
AR (1) AR059355A1 (es)
AU (1) AU2007212429A1 (es)
BR (1) BRPI0707537A2 (es)
CA (1) CA2641609A1 (es)
CR (1) CR10186A (es)
GT (1) GT200800151A (es)
IL (1) IL193157A0 (es)
NO (1) NO20083492L (es)
PA (1) PA8713501A1 (es)
PE (1) PE20071232A1 (es)
RU (1) RU2008132333A (es)
TW (1) TW200800898A (es)
WO (1) WO2007092435A2 (es)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PA8713501A1 (es) 2006-02-07 2009-09-17 Wyeth Corp INHIBIDORES DE 11-BETA HIDROXIESTEROIDE DEHIDROGENASA - 11ßHSD1
AU2007231594A1 (en) * 2006-03-23 2007-10-04 Amgen Inc. 1-phenylsulfonyl-diaza heterocyclic amide compounds and their uses as modulators of hydroxsteroid dehydrogenases
WO2007135427A1 (en) * 2006-05-23 2007-11-29 Astrazeneca Ab 1,4-disubstituted piperazine and 1,4-disubstituted azepane as 11 -beta-hydroxysteroid dehydrogenase 1 inhibitors
CL2007003223A1 (es) * 2006-11-10 2008-01-11 Wyeth Corp Compuestos derivados de piperidinil 4-arilsulfonamidas n-sustituidas, que actuan como moduladores de la proteina sfrp-1; proceso para preparar los compuestos; co mposicion farmaceutica que comprende a dichos copmpuestos y uso de los compuestos para preparar medicamentos para el tratamiento de enfermedades.
CA2677656A1 (en) * 2007-02-07 2008-08-14 Wyeth Method for preparing halogenated amines
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
NZ583495A (en) 2007-09-20 2011-11-25 Irm Llc Compounds and compositions as modulators of gpr119 activity
JP5374377B2 (ja) * 2007-10-18 2013-12-25 武田薬品工業株式会社 複素環化合物
CN101597278B (zh) 2008-06-04 2013-04-17 中国中化股份有限公司 酰胺类化合物及其制备与应用
GB0818241D0 (en) * 2008-10-06 2008-11-12 Cancer Res Technology Compounds and their use
AR074318A1 (es) * 2008-11-14 2011-01-05 Nycomed Gmbh Derivados heterociclicos de pirazolona, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de enfermedades de las vias respiratorias.
WO2010141550A2 (en) * 2009-06-04 2010-12-09 Wyeth Llc 11-beta hsd1 inhibitors
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
CN103096893B (zh) 2010-06-04 2016-05-04 阿尔巴尼分子研究公司 甘氨酸转运体-1抑制剂、其制备方法及其用途
WO2011157827A1 (de) 2010-06-18 2011-12-22 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
WO2012120054A1 (de) 2011-03-08 2012-09-13 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2683700B1 (de) 2011-03-08 2015-02-18 Sanofi Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2683699B1 (de) 2011-03-08 2015-06-24 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2683704B1 (de) 2011-03-08 2014-12-17 Sanofi Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120052A1 (de) 2011-03-08 2012-09-13 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
CN103619825B (zh) * 2011-07-01 2015-10-14 瑞敏德股份有限公司 可用于治疗神经退化性疾病的1,2,4-噻二唑-5-基哌嗪衍生物
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
US10092574B2 (en) 2012-09-26 2018-10-09 Valorisation-Recherche, Limited Partnership Inhibitors of polynucleotide repeat-associated RNA foci and uses thereof
JO3805B1 (ar) 2013-10-10 2021-01-31 Araxes Pharma Llc مثبطات كراس جي12سي
JP6339416B2 (ja) * 2014-05-28 2018-06-06 国立大学法人 名古屋工業大学 光学活性スルホンアミド誘導体の製造方法
CN104974084A (zh) * 2015-07-19 2015-10-14 佛山市赛维斯医药科技有限公司 一类胺基二吡啶叔醇结构的11β-HSD1抑制剂及其用途
EP3235813A1 (en) 2016-04-19 2017-10-25 Cidqo 2012, S.L. Aza-tetra-cyclo derivatives
EP3573964A1 (en) * 2017-01-26 2019-12-04 Araxes Pharma LLC Benzothiophene and benzothiazole compounds and methods of use thereof
US11136308B2 (en) 2017-01-26 2021-10-05 Araxes Pharma Llc Substituted quinazoline and quinazolinone compounds and methods of use thereof
EP3573971A1 (en) 2017-01-26 2019-12-04 Araxes Pharma LLC 1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1yl)prop-2-en-1-one derivatives and similar compounds as kras g12c modulators for treating cancer
US11274093B2 (en) 2017-01-26 2022-03-15 Araxes Pharma Llc Fused bicyclic benzoheteroaromatic compounds and methods of use thereof
US11639346B2 (en) 2017-05-25 2023-05-02 Araxes Pharma Llc Quinazoline derivatives as modulators of mutant KRAS, HRAS or NRAS
MX2019013954A (es) 2017-05-25 2020-08-31 Araxes Pharma Llc Inhibidores covalentes de kras.
GB201713780D0 (en) * 2017-08-29 2017-10-11 E-Therapeutics Plc Modulators of hedgehog (Hh) signalling pathway
MX2021000887A (es) 2018-08-01 2021-03-31 Araxes Pharma Llc Compuestos espiroheterociclicos y metodos de uso de los mismos para el tratamiento de cancer.
TWI838401B (zh) 2018-09-12 2024-04-11 瑞士商諾華公司 抗病毒性吡啶并吡𠯤二酮化合物
US20220024891A1 (en) * 2018-12-04 2022-01-27 The Board Of Regents Of The University Of Texas System Therapeutics targeting mutant adenomatous polyposis coli (apc) for the treatment of cancer
CN111943893B (zh) * 2019-05-17 2024-07-26 南京爱德程医药科技有限公司 4,7-二氮杂螺[2,5]辛烷类化合物的合成方法
PL3770201T3 (pl) * 2019-07-22 2023-09-25 Evonik Operations Gmbh Membrana polimerowa przewodząca aniony
AU2020353055B2 (en) 2019-09-26 2024-03-07 Gilead Sciences, Inc. Antiviral pyrazolopyridinone compounds
EP4081509A4 (en) * 2019-12-24 2024-01-03 Zydus Lifesciences Limited NOVEL COMPOUNDS SUITABLE FOR THE TREATMENT OF DYSLIPIDEMIA
CA3229226A1 (en) 2021-08-18 2023-02-23 Chemocentryx, Inc. Aryl sulfonyl compounds as ccr6 inhibitors
US12018016B2 (en) 2021-08-18 2024-06-25 Amgen Inc. Aryl sulfonyl (hydroxy) piperidines as CCR6 inhibitors

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2875205A (en) * 1959-02-24 Chj-chj
ZA813332B (en) * 1980-06-21 1982-05-26 Pfizer Larvicides and isecticides
JPS6081168A (ja) * 1983-10-13 1985-05-09 Asahi Chem Ind Co Ltd アミジン誘導体
FR2553414B1 (fr) * 1983-10-18 1986-08-14 Choay Sa Nouveaux benzenesulfonamides n-cyclises, leur procede de preparation et leur utilisation comme substance active de compositions pharmaceutiques
US4857644A (en) 1988-06-09 1989-08-15 American Home Products Corporation Aryl sulfonopiperazines as anti-inflammatory agents
WO1993012086A1 (en) * 1991-12-11 1993-06-24 Ss Pharmaceutical Co., Ltd. Arylamide derivative
EP0661266A1 (en) 1993-12-27 1995-07-05 Toa Eiyo Ltd. Substituted cyclic amine compounds as 5HT2 antagonists
US5464788A (en) 1994-03-24 1995-11-07 Merck & Co., Inc. Tocolytic oxytocin receptor antagonists
AU715658B2 (en) 1996-04-03 2000-02-10 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US6063930A (en) 1996-04-03 2000-05-16 Merck & Co., Inc. Substituted imidazole compounds useful as farnesyl-protein transferase inhibitors
CA2251955A1 (en) 1996-04-18 1997-10-23 Nancy E. Kohl A method of treating cancer
EP0934270A1 (en) 1996-05-30 1999-08-11 Merck & Co., Inc. A method of treating cancer
EP0973396A4 (en) 1997-04-07 2001-02-07 Merck & Co Inc METHOD FOR TREATING CANCER
US6297239B1 (en) 1997-10-08 2001-10-02 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
WO2000017163A1 (fr) 1998-09-22 2000-03-30 Yamanouchi Pharmaceutical Co., Ltd. Derives de cyanophenyle
WO2000025789A1 (en) 1998-10-29 2000-05-11 Merck & Co., Inc. A method of treating endometriosis
US6465468B1 (en) * 1999-03-22 2002-10-15 Darwin Discovery Limited Hydroxamic and carboxylic acid derivatives
WO2001066534A2 (en) 2000-03-09 2001-09-13 Abbott Laboratories Cyclic and bicyclic diamino histamine-3 receptor antagonists
JP2001261657A (ja) 2000-03-17 2001-09-26 Yamanouchi Pharmaceut Co Ltd シアノフェニル誘導体
JP2001328938A (ja) 2000-03-17 2001-11-27 Yamanouchi Pharmaceut Co Ltd シアノフェニル誘導体を有効成分とする医薬
DE50011776D1 (de) * 2000-06-16 2006-01-05 Baumueller Anlagen Systemtech Verfahren zum automatischen erzeugen mehrerer elektrischer impulse anhand numerischer vorgabewerte, insbesondere als inkrementalgeber-nachbildung
US7179912B2 (en) 2000-09-01 2007-02-20 Icos Corporation Materials and methods to potentiate cancer treatment
EP1217000A1 (en) 2000-12-23 2002-06-26 Aventis Pharma Deutschland GmbH Inhibitors of factor Xa and factor VIIa
GB0108591D0 (en) 2001-04-05 2001-05-23 Merck Sharp & Dohme Therapeutic agents
EA006225B1 (ru) 2001-08-21 2005-10-27 Мерк Шарп Энд Домэ Лимитед Новые циклогексилсульфоны
GB0120347D0 (en) 2001-08-21 2001-10-17 Merck Sharp & Dohme Therapeutic agents
AU2002353716A1 (en) 2001-11-22 2003-06-10 Biovitrum Ab Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
CN1649855A (zh) 2001-11-22 2005-08-03 比奥维特罗姆股份公司 11－β－羟基类固醇脱氢酶1型抑制剂
PL220783B1 (pl) 2002-03-13 2016-01-29 Janssen Pharmaceutica Nv Pochodna sulfonylowa, jej zastosowanie i sposób wytwarzania oraz kompozycja farmaceutyczna
CN1681763A (zh) 2002-07-27 2005-10-12 阿斯特拉曾尼卡有限公司 化合物
BR0315166A (pt) 2002-10-11 2005-08-16 Astrazeneca Ab Uso de um composto ou de um sal farmaceuticamente aceitável do mesmo, composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, e, método para produzir um efeito inibidor de 11betahsd1 em um animal de sangue quente, tal como o homem, que necessita de tratamento
AU2003276458A1 (en) 2002-11-07 2004-06-07 Astrazeneca Ab 2-oxo-ethanesulfonamide derivates
TW200503994A (en) 2003-01-24 2005-02-01 Novartis Ag Organic compounds
US20060258683A1 (en) 2003-04-07 2006-11-16 Liu Kevin Para-sulfonyl substituted phenyl compounds as modulators of ppars
JP2006522750A (ja) * 2003-04-11 2006-10-05 ノボ　ノルディスク　アクティーゼルスカブ 代謝性症候群ならびに関連の疾患および障害を治療するために、１１β−ヒドロキシステロイドデヒドロゲナーゼ１型阻害剤および抗高血圧剤を使用する併用療法
WO2004089471A2 (en) 2003-04-11 2004-10-21 Novo Nordisk A/S NEW PYRAZOLO[1,5-a] PYRIMIDINES DERIVATIVES AND PHARMACEUTICAL USE THEREOF
JP4884219B2 (ja) 2003-07-29 2012-02-29 ゼノン・ファーマシューティカルズ・インコーポレイテッド ピリジル誘導体および治療剤としてのその用途
KR20060036106A (ko) 2003-07-30 2006-04-27 제논 파마슈티칼스 인크. 피리딜 유도체 및 그의 치료제로서의 용도
EP2316828A1 (en) 2003-07-30 2011-05-04 Xenon Pharmaceuticals Inc. Piperazine derivatives and their use as therapeutic agents
US20050124625A1 (en) 2003-10-21 2005-06-09 Salvati Mark E. Piperazine derivatives and their use as modulators of nuclear hormone receptor function
GB0325956D0 (en) 2003-11-06 2003-12-10 Addex Pharmaceuticals Sa Novel compounds
EP1703908A4 (en) 2003-12-22 2009-07-08 Amgen Inc ARYLSULFONAMIDE COMPOUNDS AND RELATED APPLICATIONS
US7875642B2 (en) 2004-01-26 2011-01-25 Merck Sharp & Dohme Corp. Crystalline forms of an inhibitor of 11-β-hydroxysteroid dehydrogenase type 1
EP1744751A4 (en) 2004-03-18 2010-03-10 Brigham & Womens Hospital TREATMENT OF SYNUCLEINOPATHIES
AR048523A1 (es) 2004-04-07 2006-05-03 Kalypsys Inc Compuestos con estructura de aril sulfonamida y sulfonilo como moduladores de ppar y metodos para tratar trastornos metabolicos
MXPA06011868A (es) 2004-04-14 2007-03-21 Amgen Inc Aril sulfonas y usos relacionados con las mismas.
CA2561858A1 (en) 2004-04-20 2005-12-15 Amgen Inc. Arylsulfonamides and uses related thereto
TWI350168B (en) 2004-05-07 2011-10-11 Incyte Corp Amido compounds and their use as pharmaceuticals
JP2007538106A (ja) 2004-05-20 2007-12-27 イーラン ファーマスーティカルズ、インコーポレイテッド γセクレターゼのＮ−環式スルホンアミド阻害剤
JP2008504274A (ja) 2004-06-24 2008-02-14 インサイト・コーポレイション アミド化合物およびその医薬としての使用
CA2589565A1 (en) 2004-06-24 2006-01-05 Incyte Corporation Amido compounds and their use as pharmaceuticals
US20050288338A1 (en) 2004-06-24 2005-12-29 Wenqing Yao Amido compounds and their use as pharmaceuticals
US8071624B2 (en) 2004-06-24 2011-12-06 Incyte Corporation N-substituted piperidines and their use as pharmaceuticals
AU2005258248A1 (en) 2004-06-24 2006-01-05 Incyte Corporation Amido compounds and their use as pharmaceuticals
EP1768954A4 (en) 2004-06-24 2008-05-28 Incyte Corp 2-METHYLPROPANAMIDES AND THEIR USE AS PHARMACEUTICALS
NZ551859A (en) * 2004-06-28 2010-05-28 Hoffmann La Roche Pyrimidine derivatives as 11beta-HSD1 inhibitors
MX2007000040A (es) 2004-06-30 2007-03-07 Schering Corp N-arilsulfonilaminas heterociclicas sustituidas como inhibidores de gamma-secretasas.
CA2574875C (en) 2004-07-28 2010-09-28 Kurt Amrein Aryl-pyridine derivatives as 11-beta hsd1 inhibitors
US20060025445A1 (en) 2004-08-02 2006-02-02 Xiang Jason S 11-Beta HSD1 inhibitors
CA2575561A1 (en) 2004-08-10 2006-02-23 Incyte Corporation Amido compounds and their use as pharmaceuticals
WO2006034441A1 (en) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors
EP2316457A1 (en) 2004-09-20 2011-05-04 Xenon Pharmaceuticals Inc. Pyridine derivatives for inhibiting human stearoyl-coa-desaturase
WO2006048771A1 (en) 2004-11-04 2006-05-11 Addex Pharmaceuticals Sa Novel tetrazole derivatives as positive allosteric modulators of metabotropic glutamate receptors
GB0510143D0 (en) 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds A1
GT200600046A (es) 2005-02-09 2006-09-25 Terapia de combinacion
EP1866298A2 (en) 2005-03-31 2007-12-19 Takeda San Diego, Inc. Hydroxysteroid dehydrogenase inhibitors
WO2007055942A2 (en) * 2005-11-03 2007-05-18 Merck & Co., Inc. Substituted nicotinamide compounds
WO2007070506A2 (en) * 2005-12-14 2007-06-21 Amgen Inc. Diaza heterocyclic sulfonamide derivatives and their uses
JP2009521448A (ja) 2005-12-21 2009-06-04 シェーリング コーポレイション ヒスタミンｈ３アンタゴニストとして有用なフェノキシピペリジンおよびそのアナログ
PA8713501A1 (es) 2006-02-07 2009-09-17 Wyeth Corp INHIBIDORES DE 11-BETA HIDROXIESTEROIDE DEHIDROGENASA - 11ßHSD1
EP2040709A2 (en) 2006-07-19 2009-04-01 Osurf Selective androgen receptor modulators, analogs and derivatives thereof and uses thereof

Also Published As

Publication number Publication date
NO20083492L (no) 2008-10-28
GT200800151A (es) 2008-11-03
PE20071232A1 (es) 2008-02-18
WO2007092435A3 (en) 2007-12-27
CA2641609A1 (en) 2007-08-16
BRPI0707537A2 (pt) 2011-05-03
KR20080093072A (ko) 2008-10-17
US20100029648A1 (en) 2010-02-04
AU2007212429A1 (en) 2007-08-16
TW200800898A (en) 2008-01-01
CN101400653A (zh) 2009-04-01
CR10186A (es) 2008-10-29
JP2009526059A (ja) 2009-07-16
IL193157A0 (en) 2009-02-11
RU2008132333A (ru) 2010-03-20
US7632838B2 (en) 2009-12-15
EP1981848A2 (en) 2008-10-22
AR059355A1 (es) 2008-03-26
WO2007092435A2 (en) 2007-08-16
US20070219198A1 (en) 2007-09-20

Similar Documents

Publication Publication Date Title
PA8713501A1 (es) INHIBIDORES DE 11-BETA HIDROXIESTEROIDE DEHIDROGENASA - 11ßHSD1
MA33803B1 (fr) Inhibiteur de bromodomaine de benzodiazépine
BRPI1015043A2 (pt) derivados de diazahomoadamantano e métodos de uso dos mesmos
MA32508B1 (fr) Composes organiques
EA200700168A1 (ru) Производные замещенной циклической мочевины, их получение и их фармацевтическое применение в качестве ингибиторов киназы
EA200971051A1 (ru) Ингибиторы p70 s6 киназы
EA201270257A1 (ru) Производные n1-сульфонил-5-фторпиримидинона
ATE548374T1 (de) 2'-fluor-2'-desoxytetrahydrouridine als cytidindeaminaseinhibitoren
NO20084334L (no) Farmasoytiske sammensetninger
WO2007125103A3 (en) Benzamide glucokinase activators
ATE553104T1 (de) Substituierte 1h-benzimidazol-4-carboxamide als potente parp-hemmer
EA201401193A1 (ru) Триарильные соединения и композиции, их содержащие
EA200901124A1 (ru) Соединения формулы (i) в качестве ингибиторов серинпротеазы
MA32776B1 (fr) Inhibiteurs de l'akt et de la p70 s6 kinase
EA201000329A1 (ru) Циклические депсипептиды
HK1133642A1 (en) Azaadamantane ester and carbamate derivatives and methods of use thereof
EA201270256A1 (ru) Производные т1-замещенного 5-фтор-2-оксопиримидинон-1 (2h) -карбоксамида
UA106889C2 (uk) Похідні n1-ацил-5-фторпіримідинону
MX373170B (es) Variantes de la familia il-1.
EA201291460A1 (ru) Олигобензамидные соединения и их применение
SG158091A1 (en) Imidazoazepinone compounds
EA200800070A1 (ru) Производные 2-(1h-индолилсульфанил)ариламина
EA200970472A1 (ru) Замещенные пиразолы, композиции, их содержащие, способ получения и применение
MX2009010176A (es) Derivados de aza-adamantano 4-substituidos y metodos de uso de los mismos.
RS53002B (en) ANTI-CANCER UNIT AND PHARMACEUTICAL COPMOSITION CONTAINING IT